The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
CSF neurofilament proteins in the differential diagnosis of dementia
Open accessAbstract
BACKGROUND: Neurofilament (NF) proteins are major cytoskeletal constituents of neurons. Increased CSF NF levels may reflect neuronal degeneration. OBJECTIVE: To investigate the diagnostic value of CSF NF analysis to discriminate in relatively young dementia patients between frontotemporal lobe degeneration (FTLD) and early onset Alzheimer's disease (EAD; onset < or = 65 years of age), and in elderly dementia patients between dementia with Lewy bodies (DLB) and late onset AD (LAD; onset > 65 years of age). METHODS: In CSF of 28 FTLD, 37 EAD, 18 DLB and 33 LAD patients, and 26 control subjects, we analysed NF light chain (NFL), phosphorylated NF heavy chain (pNFH), amyloid beta42 protein (Abeta42), total tau and tau phosphorylated at threonine 181 (p-tau181). RESULTS: CSF NFL levels were higher in FTLD patients compared with EAD patients (p<0.001), and diagnostic accuracy of p-tau181 and Abeta42 analysis improved with addition of NFL analysis (sensitivity 86%, specificity 100%). CSF pNFH levels were elevated in DLB, LAD and FTLD compared with controls (p<0.05) but no significant differences were found between the dementia groups. CONCLUSIONS: In the diagnostic workup of relatively young dementia patients, CSF NFL levels may play a role in the discrimination between FTLD and EAD, especially in combination with Abeta42 and p-tau181 analysis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“For instance, combination of AD CSF biomarkers (Aβ42 and p‐tau181) with CSF NfL could discriminate FTLD from AD with high performance (AUC > 0.90).”
From New developments of biofluid‐based biomarkers for routine diagnosis and disease trajectories in frontotemporal dementia (2022) · cites this paper as [73]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D. L., & Stadlan, E. (2011) · Neurology · doi:10.1212/01.wnl.0000400650.92875.cf · Cited by 9,882
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Neary, D., Snowden, J. S., Gustafson, L., Passant, U., Stuss, D., Black, S., Freedman, M., Kertesz, A., Robert, P. H., Albert, M., et al. (1998) · Neurology · doi:10.1212/wnl.51.6.1546 · Cited by 5,047
McKeith, I. G., Galasko, D., Kosaka, K., Perry, E. K., Dickson, D. W., Hansen, L. A., Salmon, D. P., Lowe, J., Mirra, S. S., Byrne, E. J., et al. (1996) · Neurology · doi:10.1212/wnl.47.5.1113 · Cited by 3,960
Weıntraub, S. (1990) · Archives of Neurology · doi:10.1001/archneur.1990.00530120075013 · Cited by 3,018
Neurofilament phosphoforms: Surrogate markers for axonal injury, degeneration and loss
Petzold, A. (2005) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2005.03.015 · Cited by 688
McKeith, I. G. (2006) · Journal of Alzheimer s Disease · doi:10.3233/jad-2006-9s347 · Cited by 625
Rosengren, L. E., Karlsson, J., Karlsson, J., Persson, L. I., & Wikkelsø, C. (1996) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1996.67052013.x · Cited by 499
Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria
Faber, R., & Neary, D. (1999) · Neurology · doi:10.1212/wnl.53.5.1158-b · Cited by 371
Elevated neurofilament levels in neurological diseases
Norgren, N., Rosengren, L., & Stigbrand, T. I. (2003) · Brain Research · doi:10.1016/s0006-8993(03)03219-0 · Cited by 351
Cited by
Sorted by citations
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Neurofilament light chain as a biomarker in neurological disorders
Gaetani, L., Blennow, K., Calabresi, P., Di Filippo, M., Parnetti, L., & Zetterberg, H. (2019) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2018-320106 · Cited by 1,334
Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia
Rohrer, J. D., Woollacott, I., Dick, K. M., Brotherhood, E., Gordón, E., Fellows, A. D., Toombs, J., Druyeh, R., Cardoso, M. J., Sebastien Ourselin, A., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003154 · Cited by 450
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Lewczuk, P., Riederer, P. F., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramírez, A., Parnetti, L., et al. (2017) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 318
Self-citationCerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease
Mattsson, N., Insel, P. S., Palmqvist, S., Portelius, E., Zetterberg, H., Weiner, M. W., Blennow, K., Hansson, O., & Initiative, T. A. D. N. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606540 · Cited by 301
Neurofilament Proteins as Biomarkers to Monitor Neurological Diseases and the Efficacy of Therapies
Yuan, A., & Nixon, R. A. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.689938 · Cited by 304
CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival
Skillbäck, T., Farahmand, B., Bartlett, J. W., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000001015 · Cited by 263
Molecular biomarkers of Alzheimer's disease: progress and prospects
Lashley, T., Schott, J. M., Weston, P. S. J., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M. S., Toombs, J., Rohrer, J. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031781 · Cited by 251
Forgrave, L. M., Ma, M., Best, J. R., & DeMarco, M. L. (2019) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1016/j.dadm.2019.08.009 · Cited by 177
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P. J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.086 · Cited by 168
Self-citationNeurofilament Light Chain as Biomarker for Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
Verde, F., Otto, M., & Silani, V. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.679199 · Cited by 160
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Tortelli, R., Ruggieri, M., Cortese, R., D’Errico, E., Capozzo, R., Leo, A., Mastrapasqua, M., Zoccolella, S., Leante, R., Livrea, P., et al. (2012) · European Journal of Neurology · doi:10.1111/j.1468-1331.2012.03777.x · Cited by 151
Alirezaei, Z., Pourhanifeh, M. H., Borran, S., Nejati, M., Mirzaei, H., & Hamblin, M. R. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01698-3 · Cited by 142
Cerebrospinal fluid neurofilament light chain protein levels in subtypes of frontotemporal dementia
Landqvist Waldö, M., Frizell Santillo, A., Passant, U., Zetterberg, H., Rosengren, L., Nilsson, C., & Englund, E. (2013) · BMC Neurology · doi:10.1186/1471-2377-13-54 · Cited by 127
Frontotemporal Dementia, Where Do We Stand? A Narrative Review
Antonioni, A., Raho, E. M., Lopriore, P., Pace, A. P., Latino, R. R., Assogna, M., Mancuso, M., Gragnaniello, D., Granieri, E., Pugliatti, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411732 · Cited by 133
Development of disease-modifying drugs for frontotemporal dementia spectrum disorders
Panza, F., Lozupone, M., Seripa, D., Daniele, A., Watling, M., Giannelli, G., & Imbimbo, B. P. (2020) · Nature Reviews Neurology · doi:10.1038/s41582-020-0330-x · Cited by 122
Dhiman, K., Blennow, K., Zetterberg, H., Martins, R. N., & Gupta, V. B. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03040-5 · Cited by 117
Rojas, J. C., Wang, P., Staffaroni, A. M., Heller, C., Cobigo, Y., Wolf, A., Goh, S.-Y. M., Ljubenkov, P. A., Heuer, H. W., Fong, J. C., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000011848 · Cited by 106
Jin, M., Cao, L., & Dai, Y. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00254 · Cited by 105
Zhao, Y., Xin, Y., Meng, S., He, Z., & Hu, W. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.04.014 · Cited by 105
Dhiman, K., Gupta, V. B., Villemagne, V. L., Eratne, D., Graham, P. L., Fowler, C., Bourgeat, P., Li, Q., Collins, S., Bush, A. I., et al. (2020) · Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring · doi:10.1002/dad2.12005 · Cited by 93
Irwin, D. J., Trojanowski, J. Q., & Grossman, M. (2013) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2013.00006 · Cited by 96
Aluise, C. D., Robinson, R. A. S., & Butterfield, D. A. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2008.07.008 · Cited by 94
Zerr, I., Schmitz, M., Karch, A., Villar‐Piqué, A., Kanata, Ε., Golańska, E., Lucena, D. D., Karsanidou, A., Hermann, P., Knipper, T., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.12.008 · Cited by 88
Neurofilaments in disease: what do we know?
Gordon, B. A. (2020) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2020.02.001 · Cited by 82
EFNS guidelines on disease‐specific CSF investigations
Deisenhammer, F., Egg, R., Giovannoni, G., Hemmer, B., Petzold, A., Sellebjerg, F. T., Teunissen, C. E., & Tumani, H. (2009) · European Journal of Neurology · doi:10.1111/j.1468-1331.2009.02595.x · Cited by 79
Younes, K., & Miller, B. L. (2020) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2020.02.006 · Cited by 76
Biological fluid biomarkers in neurodegenerative parkinsonism
Eller, M., & Williams, D. R. (2009) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.135 · Cited by 75
Jellinger, K. A., Janetzky, B., Attems, J., & Kienzl, E. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00313.x · Cited by 72
Chhatwal, J. P., Schultz, A. P., Dang, Y., Ostaszewski, B., Liu, L., Yang, H.-S., Johnson, K. A., Sperling, R. A., & Selkoe, D. J. (2020) · Nature Communications · doi:10.1038/s41467-020-19543-w · Cited by 60
The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases
Baldacci, F., Mazzucchi, S., Vecchia, A. D., Giampietri, L., Giannini, N., Koronyo‐Hamaoui, M., Ceravolo, R., Siciliano, G., Bonuccelli, U., Elahi, F. M., et al. (2020) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2020.1731306 · Cited by 65
Applying fluid biomarkers to Alzheimer's disease
Zetterberg, H. (2017) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00007.2017 · Cited by 65
Biomarkers for diseases with TDP-43 pathology
Steinacker, P., Barschke, P., & Otto, M. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.10.003 · Cited by 57
Goossens, J., Bjerke, M., Mossevelde, S. V., den Bossche, T. V., Goeman, J., Vil, B. B. D., Sieben, A., Martin, J., Cras, P. P., Deyn, P. P. D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0364-0 · Cited by 59
Su, W., Chen, H. B., Li, S. H., & Wu, D. Y. (2011) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2011.11.002 · Cited by 57
Zanier, E. R., Refai, D., Zipfel, G. J., Zoerle, T., Longhi, L. G., Esparza, T. J., Spinner, M. L., Bateman, R. J., Brody, D. L., & Stocchetti, N. (2010) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.177667 · Cited by 57
Fialová, L., Bartoš, A., Švarcová, J., Zimová, D., Kotoucova, J., & Malbohan, I. M. (2013) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2013.06.010 · Cited by 58
Rivero‐Santana, A., Ferreira, D., Perestelo‐Pérez, L., Westman, E., Wahlund, L., Sarría‐Santamera, A., & Serrano-Aguilar, P. G. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160366 · Cited by 60
The role of neurofilament light chain in frontotemporal dementia: a meta-analysis
Karantali, E., Kazis, D. A., Chatzikonstantinou, S., Petridis, F., & Mavroudis, I. A. (2020) · Aging Clinical and Experimental Research · doi:10.1007/s40520-020-01554-8 · Cited by 56
Lu, C., Petzold, A., Kalmár, B., Dick, J. R. T., Malaspina, A., & Greensmith, L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0040998 · Cited by 55
Is there a CSF biomarker profile related to depression in elderly women?
Gudmundsson, P., Skoog, I. G., Wærn, M., Blennow, K., Zetterberg, H., Rosengren, L., & Gustafson, D. (2010) · Psychiatry Research · doi:10.1016/j.psychres.2008.11.012 · Cited by 55
del Campo, M., Zetterberg, H., Gandy, S., Onyike, C. U., Oliveira, F., Udeh‐Momoh, C., Lleó, A., Teunissen, C. E., & Pijnenburg, Y. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12643 · Cited by 52
Self-citationReview: Fluid biomarkers for frontotemporal dementias
Zetterberg, H., van Swieten, J. C., Boxer, A. L., & Rohrer, J. D. (2019) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12530 · Cited by 48
Skillbäck, T. B., Zetterberg, H., Blennow, K., & Mattsson, N. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt212 · Cited by 49
Update on the core and developing cerebrospinal fluid biomarkers for Alzheimer disease
Leko, M. B., Štrac, D. Š., Mück‐Šeler, D., Pivac, N., Stanić, G., Hof, P. R., & Šimić, G. (2014) · Croatian Medical Journal · doi:10.3325/cmj.2014.55.347 · Cited by 48
Neurochemical biomarkers in the differential diagnosis of movement disorders
Mollenhauer, B., & Trenkwalder, C. (2009) · Movement Disorders · doi:10.1002/mds.22510 · Cited by 45
CSF Neurofilament Proteins Levels are Elevated in Sporadic Creutzfeldt-Jakob Disease
van Eijk, J. J. J., Everbroeck, B. V., Abdo, W. F., Kremer, B. P. H., & Verbeek, M. M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-090649 · Cited by 41
Self-citationBruno, D., Pomara, N., Nierenberg, J. J., Ritchie, J., Lutz, M. W., Zetterberg, H., & Blennow, K. (2011) · Experimental Gerontology · doi:10.1016/j.exger.2011.09.008 · Cited by 40
Menculini, G., Chipi, E., Paoletti, F. P., Gaetani, L., Nigro, P., Simoni, S., Mancini, A., Tambasco, N., Filippo, M. D., Tortorella, A. A. V., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22094440 · Cited by 44
Wang, Z., Wang, R., Li, Y., Li, M., Zhang, Y., Jiang, L., Fan, J., Wang, Q., & Yang, D. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.631738 · Cited by 39
Cerebrospinal Fluid Biomarkers for Dementia with Lewy Bodies
Mukaetova‐Ladinska, E. B., Monteith, R., & Perry, E. K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/536538 · Cited by 37
Neurofilaments contribution in clinic: state of the art
Delaby, C., Bousiges, O., Bouvier, D., Fillée, C., Fourier, A., Mondésert, E., Nezry, N., Omar, S., Quadrio, I., Rucheton, B., et al. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.1034684 · Cited by 38
Cousins, K. A. Q., Phillips, J. S., Irwin, D. J., Lee, E. B., Wolk, D. A., Shaw, L. M. J., Zetterberg, H., Blennow, K., Burke, S., Kinney, N. G., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12233 · Cited by 38
Biomarkers in biological fluids for dementia with Lewy bodies
Schade, S., & Mollenhauer, B. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0072-3 · Cited by 36
Blood Biomarkers for Alzheimer’s Disease: Much Promise, Cautious Progress
Keshavan, A., Heslegrave, A., Zetterberg, H., & Schott, J. M. (2017) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-016-0241-0 · Cited by 34
Hildebrandt, H., Haldenwanger, A., & Eling, P. (2009) · Journal of Alzheimer s Disease · doi:10.3233/jad-2009-0931 · Cited by 32
Neurochemical biomarkers in the diagnosis of frontotemporal lobar degeneration: an update
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13669 · Cited by 30
Recent advances in understanding frontotemporal degeneration
Borroni, B., & Benussi, A. (2019) · F1000Research · doi:10.12688/f1000research.20330.1 · Cited by 30
Comparison of CSF and plasma NfL and pNfH for Alzheimer's disease diagnosis: a memory clinic study
Vrillon, A., Ashton, N. J., Karikari, T. K., Götze, K., Cognat, E., Dumurgier, J., Lilamand, M., Zetterberg, H., Blennow, K., & Paquet, C. (2024) · Journal of Neurology · doi:10.1007/s00415-023-12066-6 · Cited by 28
Oeckl, P., Steinacker, P., Feneberg, E., & Otto, M. (2014) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2014.12.010 · Cited by 28
Fluid Candidate Biomarkers for Alzheimer’s Disease: A Precision Medicine Approach
Prete, E. D., Beatino, M. F., Campese, N., Giampietri, L., Siciliano, G., Ceravolo, R., & Baldacci, F. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040221 · Cited by 29
Duran-Aniotz, C. A., Orellana, P., Rodríguez, T. L., Henríquez, F., Cabello, V., Aguirre-Pinto, M. F., Escobedo, T., Takada, L. T., Piña‐Escudero, S. D., López, O. L., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.663407 · Cited by 26
Brain perfusion SPECT correlates with CSF biomarkers in Alzheimer’s disease
Habert, M., de Souza, L. C., Lamari, F., Daragon, N., Désarnaud, S., Jardel, C., Dubois, B., & Sarazin, M. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-009-1285-8 · Cited by 25
Zetterberg, H., Lautner, R., Skillbäck, T. B., Rosén, C., Shahim, P., Mattsson, N., & Blennow, K. (2014) · Advances in clinical chemistry · doi:10.1016/b978-0-12-800141-7.00005-x · Cited by 21
Brinkmalm, A., Portelius, E., Brinkmalm, G., Pannee, J., Dahlén, R., Gobom, J., Blennow, K., & Zetterberg, H. (2018) · Journal of Neurochemistry · doi:10.1111/jnc.14594 · Cited by 21
Kou, W., Li, S., Yan, R., Zhang, J., Wan, Z., & Feng, T. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13051-x · Cited by 22
Frontotemporal dementia. How to deal with its diagnostic complexity?
Antonioni, A., Raho, E. M., Granieri, E., & Koch, G. (2025) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2025.2461758 · Cited by 22
Han, T., Cong, H., Yu, B., & Shen, Y. (2022) · BioFactors · doi:10.1002/biof.1875 · Cited by 18
Liu, H.-C., Lin, W., Chiu, M., Lu, C.-H., Lin, C.-Y., & Yang, S. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234519 · Cited by 18
The Alzheimer's Disease Neuroimaging Initiative Neuropathology Core: An update
Perrin, R. J., Franklin, E. E., Bernhardt, H., Burns, A., Schwetye, K. E., Cairns, N. J., Baxter, M., Weiner, M. W., Morris, J. C., & Initiative, A. D. N. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14253 · Cited by 17
Emerging Biomarkers in Cognition
Wicklund, M. R., & Petersen, R. C. (2013) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2013.07.006 · Cited by 17
Added value of cerebrospinal fluid multimarker analysis in diagnosis and progression of dementia
Álvarez, I., Díez-Fairén, M., Aguilar, M., González, J. M., Ysamat, M., Tartari, J. P., Cárcel, M., Alonso, Á., Brix, B., Arendt, P., et al. (2020) · European Journal of Neurology · doi:10.1111/ene.14658 · Cited by 17
Prodromal and Early bvFTD: Evaluating Clinical Features and Current Biomarkers
Katisko, K., Cajanus, A., Korhonen, T., Remes, A. M., Haapasalo, A., & Solje, E. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00658 · Cited by 18
Neurofilaments and tau proteins in cerebrospinal fluid and serum in dementias and neuroinflammation
Fialová, L., Bartoš, A., & Švarcová, J. (2017) · Biomedical Papers · doi:10.5507/bp.2017.038 · Cited by 16
Serum peptides as candidate biomarkers for dementia with Lewy bodies
Suzuki, I., Noguchi, M., Arito, M., Sato, T., Omoteyama, K., Maedomari, M., Hasegawa, H., Suematsu, N., Okamoto, K., Kato, T., et al. (2015) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4274 · Cited by 14
Cerebrospinal Fluid Analysis Should Be Considered in Patients with Cognitive Problems
Zetterberg, H., Mattsson, N., & Blennow, K. (2010) · International Journal of Alzheimer s Disease · doi:10.4061/2010/163065 · Cited by 14
CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers
Rostgaard, N., Roos, P., Portelius, E., Blennow, K., Zetterberg, H., Simonsen, A. H., & Nielsen, J. E. (2017) · Neurology · doi:10.1212/wnl.0000000000004799 · Cited by 13
Wu, C., Pan, X.-S., Su, L.-Y., & Yang, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241813771 · Cited by 12
Cerebrospinal fluid in the dementias
Zetterberg, H., Rohrer, J. D., & Schott, J. M. (2017) · Handbook of clinical neurology · doi:10.1016/b978-0-12-804279-3.00006-x · Cited by 13
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12
Fluid Biomarkers of Frontotemporal Lobar Degeneration
van der Ende, E. L., & Swieten, J. C. V. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-51140-1_9 · Cited by 11
Biomarkers Differentiating Dementia with Lewy Bodies from Other Dementias: A Meta-Analysis
Mishima, A., Nihashi, T., Ando, Y., Kawai, H., Kato, T., Ito, K., & Terasawa, T. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150675 · Cited by 10
Bridging Molecular Genetics and Biomarkers in Lewy Body and Related Disorders
Ho, G. J., Liang, W., Waragai, M., Sekiyama, K., Masliah, E., & Hashimoto, M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/842475 · Cited by 9
Biofluid biomarkers for Alzheimer’s disease
Wang, S., Xie, S., Zheng, Q., Zhang, Z., Wang, T., & Zhang, G. (2024) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2024.1380237 · Cited by 9
CSF tau proteins in differential diagnosis of dementia
Boban, M., Šarac, H., Mimica, N., Mladinov, M., Süßmair, C., Ackl, N., Bader, B., Huzak, M., Danek, A., Hof, P. R., et al. (2010) · Translational Neuroscience · doi:10.2478/v10134-010-0013-z · Cited by 8
Kühle, J., & Petzold, A. (2011) · Expert Opinion on Medical Diagnostics · doi:10.1517/17530059.2011.592184 · Cited by 8
Kaur, G., Poljak, A., Braidy, N., Crawford, J. D., Lo, J., & Sachdev, P. S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200052 · Cited by 10
Neurofilament heavy phosphorylated epitopes as biomarkers in ageing and neurodegenerative disease
Paoli, L. F. D., Kirkcaldie, M., King, A. E., & Collins, J. M. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16261 · Cited by 7
Olofsson, J., Bergström, S., Mravinacová, S., Kläppe, U., Öijerstedt, L., Zetterberg, H., Blennow, K., Ingre, C., Nilsson, P., & Månberg, A. (2024) · Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration · doi:10.1080/21678421.2024.2428930 · Cited by 9
Walia, N., Eratne, D., Loi, S. M., Li, Q.-X., Varghese, S., Malpas, C. B., Walterfang, M., Evans, A. H., Parker, S., Collins, S. J., et al. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120088 · Cited by 6
Olsson, B., Schott, J. M., Blennow, K., & Zetterberg, H. (2017) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2017.1341311 · Cited by 7
Alberti, C., Gonzalez, J., Maldonado, H., Medina, F., Barriga, A., Garcı́a, L., Kettlun, A. M., Collados, L., Puente, J., Cartier, L., et al. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0262 · Cited by 6
Clinical Use of Cerebrospinal Fluid Biomarkers in Alzheimer’s Disease
Zetterberg, H., Lunn, M. P., & Herukka, S. (2012) · Biomarkers in Medicine · doi:10.2217/bmm.12.47 · Cited by 5
Biomarkører i spinalvæske ved demens
Skogseth, R. E., Fladby, T., Mulugeta, E., & Aarsland, D. (2011) · Tidsskrift for Den norske legeforening · doi:10.4045/tidsskr.10.0104 · Cited by 5
Serum neurofilament heavy chain predicts post-stroke cognitive impairment
Qiao, H., Wang, S., Tao, M., Fan, H., Zhao, T., Du, Y., & Dong, M. (2025) · Scientific Reports · doi:10.1038/s41598-025-96952-1 · Cited by 4
Systematic review of differentially abundant proteins in people with Lewy body dementia
Farr, L. M., Thorpe, N., Brinda, E. M., Al‐Balushi, N., Sohail, M., & Rajkumar, A. P. (2025) · Acta Neuropsychiatrica · doi:10.1017/neu.2025.15 · Cited by 5
Dutysheva, E. A., Викторовна, З. А., Valko, M. A., Antipina, E. O., Zimatkin, S. M., Margulis, B. A., Guzhova, I. V., & Lazarev, V. F. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311541 · Cited by 3
Feneberg, E., Steinacker, P., Lehnert, S., Neumann, M., & Otto, M. (2012) · Journal of Laboratory Medicine · doi:10.1515/jlm-2011-0009 · Cited by 3
Metadata
- Authors
- de Jong, D., Jansen, R. W. M. M., Pijnenburg, Y. A. L., van Geel, W. J. A., Borm, G. F., Kremer, H. P. H., & Verbeek, M. M.
- Affiliations
- Radboud University Medical Center (NL)
- Amsterdam UMC Location Vrije Universiteit Amsterdam (NL)
- Corresponding author
- Verbeek, M M
- Venue
- Journal of Neurology, Neurosurgery & Psychiatry
- Publisher
- BMJ
- Published
- 2007-09-01
- Volume
- 78
- Issue
- 9
- Pages
- 936-938
- ISSN
- 0022-3050 (ISSN-L)
- PMC
- PMC2117885
- OpenAlex
- W2004037240
- Cited by
- 120
- References
- 25
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 4 · 2023: 3 · 2022: 4 · 2021: 10 · 2020: 13 · 2019: 9 · 2018: 7 · 2017: 6 · 2016: 7 · 2015: 4 · 2014: 5 · 2013: 7 · 2012: 7
- FWCI
- 3.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neurology Neurosurgery & Psychiatry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Funders
- American Health Assistance Foundation
- Hersenstichting
- Alzheimer Nederland
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- neurofilament light chain, cerebrospinal fluid biomarkers, differential diagnosis of dementia, frontotemporal lobar degeneration, early-onset Alzheimer's disease, dementia with Lewy bodies, late-onset Alzheimer's disease, amyloid-beta 42, tau phosphorylation, p-tau181, neurodegeneration
- MeSH terms
- Age Factors, Aged, Aged, 80 and over, Alzheimer Disease, Dementia, Diagnosis, Differential, Female, Humans, Male, Middle Aged, Predictive Value of Tests, Case-Control Studies, Amyloid beta-Peptides, tau Proteins, Neurofilament Proteins, Lewy Body Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
